Konsult Pharma Services Limited 9072465 false 2023-07-01 2024-06-30 2024-06-30 The principal activity of the company is pharmaceutical product development technical and regulatory consulting Digita Accounts Production Advanced 6.30.9574.0 true true 9072465 2023-07-01 2024-06-30 9072465 2024-06-30 9072465 bus:OrdinaryShareClass1 2024-06-30 9072465 bus:OrdinaryShareClass2 2024-06-30 9072465 core:RetainedEarningsAccumulatedLosses 2024-06-30 9072465 core:ShareCapital 2024-06-30 9072465 core:CurrentFinancialInstruments 2024-06-30 9072465 core:CurrentFinancialInstruments core:WithinOneYear 2024-06-30 9072465 core:FurnitureFittingsToolsEquipment 2024-06-30 9072465 bus:SmallEntities 2023-07-01 2024-06-30 9072465 bus:AuditExemptWithAccountantsReport 2023-07-01 2024-06-30 9072465 bus:FilletedAccounts 2023-07-01 2024-06-30 9072465 bus:SmallCompaniesRegimeForAccounts 2023-07-01 2024-06-30 9072465 bus:RegisteredOffice 2023-07-01 2024-06-30 9072465 bus:Director1 2023-07-01 2024-06-30 9072465 bus:OrdinaryShareClass1 2023-07-01 2024-06-30 9072465 bus:OrdinaryShareClass2 2023-07-01 2024-06-30 9072465 bus:PrivateLimitedCompanyLtd 2023-07-01 2024-06-30 9072465 core:FurnitureFittingsToolsEquipment 2023-07-01 2024-06-30 9072465 core:OfficeEquipment 2023-07-01 2024-06-30 9072465 countries:EnglandWales 2023-07-01 2024-06-30 9072465 2023-06-30 9072465 core:FurnitureFittingsToolsEquipment 2023-06-30 9072465 2022-07-01 2023-06-30 9072465 2023-06-30 9072465 bus:OrdinaryShareClass1 2023-06-30 9072465 bus:OrdinaryShareClass2 2023-06-30 9072465 core:RetainedEarningsAccumulatedLosses 2023-06-30 9072465 core:ShareCapital 2023-06-30 9072465 core:CurrentFinancialInstruments 2023-06-30 9072465 core:CurrentFinancialInstruments core:WithinOneYear 2023-06-30 9072465 core:FurnitureFittingsToolsEquipment 2023-06-30 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 9072465

Konsult Pharma Services Limited

Unaudited Financial Statements

for the Year Ended 30 June 2024

 

Konsult Pharma Services Limited

(Registration number: 9072465)
Balance Sheet as at 30 June 2024

Note

2024
£

2023
£

Fixed assets

 

Tangible assets

4

314

702

Current assets

 

Debtors

5

20,592

13,317

Cash at bank and in hand

 

13,768

26,456

 

34,360

39,773

Creditors: Amounts falling due within one year

6

(26,971)

(40,232)

Net current assets/(liabilities)

 

7,389

(459)

Net assets

 

7,703

243

Capital and reserves

 

Called up share capital

7

100

100

Retained earnings

7,603

143

Shareholders' funds

 

7,703

243

For the financial year ending 30 June 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476.

The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006 and FRS 102 Section 1A.

Approved and authorised by the director on 14 March 2025
 

.........................................
Dr G R Kay
Director

   
 

Konsult Pharma Services Limited

Notes to the Unaudited Financial Statements for the Year Ended 30 June 2024

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is: 49 Ellis Road, Crowthorne, Berkshire, RG45 6PR.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A - 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006.

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Going concern

The financial statements have been prepared on a going concern basis.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the provision of services in the ordinary course of the company’s activities. Turnover is shown net of value added tax, rebates and discounts. The company recognises revenue when the amount of revenue can be reliably measured, it is probable that future economic benefits will flow to the entity and specific criteria have been met for each of the company's activities.

Tax

The tax expense for the period comprises current tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Tangible assets

Tangible assets are stated in the statement of financial position at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses. The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

 

Konsult Pharma Services Limited

Notes to the Unaudited Financial Statements for the Year Ended 30 June 2024

2

Accounting policies (continued)

Asset class

Depreciation method and rate

Office equipment

Straight line over 3 years

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business. Debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for impairment is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the debtor.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Creditors are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities. Creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Share capital

Ordinary shares are classified as equity. All shares are issued on a fully paid up basis.

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

3

Staff numbers

The average number of persons employed by the company (including the director) during the year, was 1 (2023 - 1).

 

Konsult Pharma Services Limited

Notes to the Unaudited Financial Statements for the Year Ended 30 June 2024

4

Tangible assets

Furniture, fittings and equipment
 £

Total
£

Cost or valuation

At 1 July 2023

3,642

3,642

At 30 June 2024

3,642

3,642

Depreciation

At 1 July 2023

2,940

2,940

Charge for the year

388

388

At 30 June 2024

3,328

3,328

Carrying amount

At 30 June 2024

314

314

At 30 June 2023

702

702

5

Debtors

Current

2024
£

2023
£

Trade debtors

14,520

-

Prepayments

812

567

Other debtors

5,260

12,750

 

20,592

13,317

6

Creditors

Creditors: amounts falling due within one year

2024
£

2023
£

Trade creditors

614

222

Taxes and social security

16,309

34,651

Directors current accounts

10,048

5,359

26,971

40,232

 

Konsult Pharma Services Limited

Notes to the Unaudited Financial Statements for the Year Ended 30 June 2024

7

Share capital

Allotted, called up and fully paid shares

2024

2023

No.

£

No.

£

Ordinary "A" shares of £1 each

75

75

75

75

Ordinary "B" shares of £1 each

25

25

25

25

100

100

100

100